Last reviewed · How we verify

NCT06230068: ExBRAC-P

ExBRAC - the Pilot Study

Completed NA Last updated 6 April 2025
What this trial tests

NA trial testing Expressive writing in Breast Cancer in 25 participants. Completed in 1 March 2025.

Timeline
26 March 2024
Primary endpoint
1 March 2025
1 March 2025

Quick facts

Lead sponsorRegion Skane
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment25
Start date26 March 2024
Primary completion1 March 2025
Estimated completion1 March 2025
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

18 and older, female only, with Breast Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The EXBRAC pilot study will investigate the quality of life of patients with breast cancer, and the effect of an intervention with expressive writing. This is a pilot study with two purposes, the first is to create a questionnaire specifically developed for the ExBRAC study, and the second to evaluate the feasibility of the expressive writing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Expressive writing

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06230068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing